Marco Egbring

Marco Egbring

Auto-generated profile, based on publicly available information

Marco Egbring

Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2016 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MEMarco Egbring
Marco Egbring
EFElmira Far
Elmira Far
MRMalgorzata Roos
Malgorzata Roos
MDMichael Dietrich
Michael Dietrich
MBMathis Brauchbar
Mathis Brauchbar
ATAndreas Trojan
Andreas Trojan
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

11 December 2019 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
AJAnnika M. Jödicke
Annika M. Jödicke
UZUrs Zellweger
Urs Zellweger
ITIvan T. Tomka
Ivan T. Tomka
TNThomas Neuer
Thomas Neuer
ICIvanka Curkovic
Ivanka Curkovic
MEMarco Egbring
Marco Egbring
Background: Rising health care costs are a major public health issue. Thus, accurately predicting future costs and understanding which factors contribute to increases in health care expenditures are important. The objective of this project was to predict patients healthcare costs development in the subsequent year and to identify factors contributing to this prediction, with a particular focus on the role of pharmacotherapy. Methods: We used 2014–2015 Swiss health insurance claims data on 373′264 adult patients to classify individuals’ changes in health care costs. We performed extensive feature generation and developed predictive models using logistic regression, boosted decision trees and neural networks. Based on the decision tree model, we performed a detailed feature importance analysis and subgroup analysis, with an emphasis on drug classes. Results: The boosted decision tree model achieved an overall accuracy of 67.6% and an area under the curve-score of 0.74; the neural network and logistic regression models performed 0.4 and 1.9% worse, respectively. Feature engineering played a key role in capturing temporal patterns in the data. The number of features was reduced from 747 to 36 with only a 0.5% loss in the accuracy. In addition to hospitalisation and outpatient physician visits, 6 drug classes and the mode of drug administration were among the most important features. Patient subgroups with a high probability of increase (up to 88%) and decrease (up to 92%) were identified. Conclusions: Pharmacotherapy provides important information for predicting cost increases in the total population. Moreover, its relative importance increases in combination with other features, including health care utilisation.

17 March 2021 in JMIR Cancer
Verified
Journal Article
Open access
ATAndreas Trojan
Andreas Trojan
BBBasil Bättig
Basil Bättig
MMMeinrad Mannhart
Meinrad Mannhart
BSBurkhardt Seifert
Burkhardt Seifert
MBMathis N Brauchbar
Mathis N Brauchbar
MEMarco Egbring
Marco Egbring
Background: Digital monitoring of treatment-related symptoms and self-reported patient outcomes is important for the quality of care among cancer patients. As mobile devices are ubiquitous nowadays, the collection of electronic patient-reported outcomes (ePROs) is gaining momentum. So far, data are lacking on the modalities that contribute to the quantity and quality of ePROs. Objective: The objective of our study was to compare the utilization of two versions of a subsequently employed mobile app for electronic monitoring of PROs and to test our hypothesis that a shared review of symptoms in patient-physician collaboration has an impact on the number of data entries. Methods: The Consilium Care app engages cancer patients to standardize reporting of well-being and treatment-related symptoms in outpatient settings. For descriptive comparison of the utilization of two slightly different app versions, data were obtained from an early breast cancer trial (version 1 of the app, n=86) and an ongoing study including patients with advanced disease (version 2 of the app, n=106). In both app versions, patients and doctors were allowed to share the information from data entries during consultations. Version 2 of the app, however, randomly selected symptoms that required a detailed and shared regular patient-doctor review in order to focus on the collection and appropriate interpretation regarding awareness and guidance for severity grading. The numbers and types of symptom entries, satisfaction with both app versions, and patients' perceived effects during consultations were included for analysis. Results: Symptom severity grading was performed according to the Common Terminology Criteria for Adverse Events (CTCAE) using a horizontal slider and was indicated in descriptive terminology in both apps, while a graphical display facilitated the illustration of symptom history charts. In total, 192 patients electronically reported 11,437 data entries on well-being and 33,380 data entries on individual symptoms. Overall, 628 (of 872 intended) requested patient-doctor symptom reviews were performed in version 2 of the app. Both the amount of data entries per patient and day for well-being (version 1 vs version 2: 0.3 vs 1.0; P<.001) and symptoms (version 1 vs version 2: 1.3 vs 1.9; P=.04) appeared significantly increased in version 2 of the app. Overall satisfaction with both app versions was high, although version 2 of the app was perceived to be more helpful in general. Conclusions: Version 2 of the app showed much better results than version 1 of the app. A request for collaborative patient-doctor symptom review is likely to affect the number of digital symptom data entries. This app shows high potential to improve the patient-doctor experience.

20 August 2012 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
EFElmira Far
Elmira Far
ICIvanka Curkovic
Ivanka Curkovic
KBKelly Byrne
Kelly Byrne
MRMalgorzata Roos
Malgorzata Roos
IEIsabelle Egloff
Isabelle Egloff
MEMarco Egbring
Marco Egbring
Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category.

7 May 2018 in Annals of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
AJAnnika M. Jödicke
Annika M. Jödicke
ICIvanka Curkovic
Ivanka Curkovic
UZUrs Zellweger
Urs Zellweger
ITIvan T. Tomka
Ivan T. Tomka
TNThomas Neuer
Thomas Neuer
MEMarco Egbring
Marco Egbring
Background: Potential drug-drug interactions (pDDIs) are described in various case reports, but few studies have evaluated the impact of specific combinations on a population level. Objective: To analyze the type and frequency of multiple contraindicated (X-pDDIs) and major interactions (D-pDDIs) and to subsequently assess the impact of the particular combination of tizanidine and ciprofloxacin on outpatient physician visits and hospitalizations. Methods: Anonymized Swiss claims data from 524 797 patients in 2014-2015 were analyzed. First, frequencies of X- and D-pDDIs were calculated. Next, a retrospective cohort study was conducted among patients prescribed tizanidine and ciprofloxacin (exposed, n = 199) or tizanidine and other antibiotics (unexposed, n = 960). Hospitalizations and outpatient physician visits within 7, 14, and 30 days after initiation of antibiotic therapy were evaluated using multiple binary logistic regression and multiple linear regression. Results: The relative frequencies of X- and D-pDDIs were 0.4% and 6.65%, respectively. In the cohort study, significant associations between exposure to tizanidine and ciprofloxacin and outpatient physician visits were identified for 14 and 30 days (odds ratio [OR] = 1.61 [95% CI = 1.17-2.24], P = 0.004, and OR = 1.59 [95% CI = 1.1-2.34], P = 0.016). A trend for increased risk of hospitalization was found for all evaluated time periods (OR = 1.68 [95% CI = 0.84-3.17], OR = 1.52 [95% CI = 0.63-3.33], and OR = 2.19 [95% CI = 0.88-5.02]). Conclusion and Relevance: The interaction between tizanidine and ciprofloxacin is not only relevant for individual patients, but also at the population level. Further investigation of the impact of other clinically relevant DDIs is necessary to improve patient safety and reduce avoidable health care utilization.

11 March 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MEMarco Egbring
Marco Egbring
EFElmira Far
Elmira Far
AKAlexander Knuth
Alexander Knuth
MRMalgorzata Roos
Malgorzata Roos
WKWilhelm Kirch
Wilhelm Kirch
GKGerd A. Kullak-Ublick
Gerd A. Kullak-Ublick